| 新型冠状病毒SARS-CoV-2及抗COVID-19药物研究进展 |
| |
| 引用本文： | 邱胤达,施泓亦,姜程曦,刘志国,李校堃. 新型冠状病毒SARS-CoV-2及抗COVID-19药物研究进展[J]. 药学进展, 2020, 0(2): 145-152 |
| |
| 作者姓名： | 邱胤达 施泓亦 姜程曦 刘志国 李校堃 |
| |
| 作者单位： | 温州医科大学药学院;温州医科大学病毒与诊疗研究院 |
| |
| 基金项目： | 国家自然科学基金(No.81973168);温州市科技计划项目(No.2018Y0465)。 |
| |
| 摘 要： | 新型冠状病毒(SARS-CoV-2)感染引发的肺炎(COVID-19)疫情严重威胁广大人民群众身体健康和生命安全,对我国的经济发展、社会稳定和对外交往产生重大影响。由于新型冠状病毒的传染性强、传播速度快、致死率较高,尚无有效疫苗和药物来防治,因此针对该病毒的疫苗与药物研发显得尤为迫切。主要围绕COVID-19的病毒来源、传播途径、临床症状和防控治疗措施,以及目前抗COVID-19药物的研究进展进行综述。
|
| 关 键 词： | SARS-CoV-2 肺炎 抗病毒药物 |
Research Progress on SARS-CoV-2 and Anti-COVID-19 Drugs |
| |
| QIU Yinda,SHI Hongyi,JIANG Chengxi,LIU Zhiguo,LI Xiao. Research Progress on SARS-CoV-2 and Anti-COVID-19 Drugs[J]. Progress in Pharmaceutical Sciences, 2020, 0(2): 145-152 |
| |
| Authors: | QIU Yinda SHI Hongyi JIANG Chengxi LIU Zhiguo LI Xiao |
| |
| Affiliation: | (School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou 325035,China;Institute of Viral Diagnosis&Therapy,Wenzhou Medical University,Wenzhou 325035,China) |
| |
| Abstract: | As a serious threat to public health, viral pneumonia caused by SARS-CoV-2 has a significant impact on China’s economic development, social stability and international exchange. Due to the strong infectivity, fast transmission and high mortality of SARSCoV-2, and especially to the current lack of effective therapies, it is particularly urgent to develop vaccines and drugs for the treatment of COVID-19. This article reviews the sources of the virus, routes of transmission, clinical symptoms, prevention and control, and the treatment of new coronavirus pneumonia, together with the current research progress on anti-COVID-19 drugs. |
| |
| Keywords: | SARS-CoV-2 pneumonia antiviral drug |
| 本文献已被 维普 等数据库收录！ |
|
